Steamboat Springs, CO, United States of America

Maxim Tsypin

USPTO Granted Patents = 20 

 

 

Average Co-Inventor Count = 3.4

ph-index = 9

Forward Citations = 223(Granted Patents)


Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents

Title: Innovator Maxim Tsypin: Pioneering Predictive Medicine in Steamboat Springs

Introduction

Maxim Tsypin is an accomplished inventor based in Steamboat Springs, Colorado, recognized for his significant contributions to the field of predictive medicine. With a portfolio of 20 patents, Tsypin has focused primarily on advancing methods for predicting patient responses to cancer treatments, particularly immune checkpoint inhibitors.

Latest Patents

Among Tsypin's most notable innovations is the predictive test for patient benefit from antibody drugs that block the ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein. This patent describes a method of predicting the response of cancer patients to these critical therapies. The process involves analyzing mass spectrometry data obtained from blood samples, where integrated intensity values are extracted from specific mass-spectral features. A classifier, implemented through programmed computing, compares these values against a training set derived from a multitude of melanoma patients. This innovation allows for the generation of class labels indicating whether a patient is likely to receive substantial benefits from antibody therapy, thereby guiding personalized treatment approaches.

Career Highlights

Maxim Tsypin currently works at Biodesix, Inc., a company devoted to advancing innovative diagnostic solutions in the realm of cancer treatment. His work there underscores a commitment to integrating cutting-edge technology with medical practices, ultimately aimed at improving patient outcomes through personalized medicine.

Collaborations

In his professional journey, Tsypin has collaborated with renowned colleagues such as Heinrich Röder and Julia Grigorieva. These partnerships enhance the interdisciplinary approach taken at Biodesix, Inc., promoting a collaborative environment that fosters innovation and expertise in the field.

Conclusion

Maxim Tsypin exemplifies the spirit of innovation, with a focus on utilizing advanced technology to improve healthcare outcomes. His work in predictive medicine not only represents significant strides in cancer treatment but also reaffirms the importance of tailored therapies in modern medicine. As we move forward, the impact of his inventions will continue to resonate in the treatment and understanding of cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…